A Brave New World: Japan Pharma and COVID-19

COVID-19 or SARS Cov-2 to be precise, has changed the world in many regards. From the way we work, to the way we do business as well as to even what used to be the simplest thing – chatting over coffee. Now everything, or at least for the time being, is either via...

Deal Makers of Japan, Volume 2

We are pleased to present the second series of the Deal Makers of Japan – Exclusive Interviews with Japan’s best dealmakers. We released our inaugural edition March 2020 and have received numerous comments from biotech/biopharma companies around the...

Deal Makers of Japan, Volume 1

Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s history and we are deeply rooted in the market. We have advised on more than a dozen transactions during our history in Japan and have successfully helped deal making between US/EU...

The Asia Factor Whitepaper

How Does a Smart Deal Maker “Play” This Region and Optimize the Capital Raising and Strategic Deal Making Opportunities? Authors: Hayato Watanabe, SVP, Head of Asia Koji Hirabata, Associate Stefanie Gan, Analyst Although their biopharma ecosystem dynamics...

Japan & China: So close yet so different

Having lived in Japan for more than 20 years, I have admittedly become perhaps a little too accustomed to the Japanese lifestyle. This is probably why after a few days in the hustle and bustle of Shanghai, I find myself looking forward to returning to the peace and...